Genenta Science 提供了初步 1/2 期试验数据，证明 GBM 肿瘤微环境成功重编程，显示 Temferon 没有剂量限制毒性，并且血液中可检测到分化细胞。 Genenta Science presents preliminary Phase 1/2 trial data demonstrating successful reprogramming of GBM tumor microenvironment, showing no dose-limiting toxicity for Temferon and detectable differentiated cells in blood.
临床阶段免疫肿瘤公司 Genenta Science 公布了其正在进行的 1/2 期临床试验的初步数据，证明胶质母细胞瘤 (GBM) 患者的肿瘤微环境已成功重新编程。 Genenta Science, a clinical-stage immuno-oncology company, has presented preliminary data from its ongoing Phase 1/2 clinical trial, demonstrating the successful reprogramming of the tumor microenvironment in glioblastoma (GBM) patients. 这是一项重大成就，因为它为实体瘤的创新治疗铺平了道路。 This is a significant achievement, as it paves the way for innovative treatments of solid tumors. 初步数据表明，没有与 Temferon 相关的剂量限制毒性，并且在外周血中可检测到 Temferon 衍生的分化细胞，这表明其具有广阔的治疗潜力。 The preliminary data indicates no dose-limiting toxicities related to Temferon, and Temferon-derived differentiated cells were detectable within the peripheral blood, suggesting a promising therapeutic potential.